Medium-term revenue synergies from this acquisition are estimated at around $100 million annually, with potential long-term increases exceeding $500 million per year.

Headquartered in Boston, Dotmatics serves over 14,000 customers globally and employs more than 800 people, providing renowned applications like GraphPad Prism and Geneious.

Dotmatics offers a platform that accelerates drug development through advanced scientific applications and multi-modal data management, facilitating AI-driven innovation.

Following the acquisition announcement, Siemens' stock saw a modest increase of 0.25%, while shares of Siemens Healthineers and Siemens Energy experienced slight declines.

Siemens plans to finance the acquisition primarily through the sale of shares in publicly traded companies, including a reduction in its stake in Siemens Healthineers from 75% to 70%.

Siemens AG has announced its acquisition of Dotmatics, a leading provider of Life Sciences R&D software, for $5.1 billion, which will enhance Siemens' AI-powered software portfolio.

This strategic move aims to accelerate customer innovation in sectors characterized by high R&D investment, aligning with Siemens' broader growth initiatives.

The acquisition is part of Siemens' ONE Tech Company program, designed to expand the Siemens Xcelerator platform into Life Sciences software, thereby improving customer focus and fostering innovation.

The deal is expected to close in the first half of fiscal year 2026, pending the necessary regulatory approvals.

This acquisition is expected to expand Siemens' total addressable market by $11 billion, driven by increasing medication needs and the demand for enhanced collaboration across value chains.

Dotmatics is projected to generate over $300 million in revenue for fiscal year 2025, with a robust adjusted EBITDA margin exceeding 40%, positively impacting Siemens' financial outlook.

Dotmatics CEO Thomas Swalla expressed enthusiasm about the acquisition, emphasizing the potential for accelerated innovation cycles in life sciences R&D through the integration of their platform with Siemens' capabilities.